A Bioequivalence (BE) Study Comparing The Commericializable And Clinical Formulations Of PF-00299804

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01313793
Recruitment Status : Completed
First Posted : March 14, 2011
Last Update Posted : June 28, 2011
Information provided by:

Brief Summary:
The study will determine if bioequivalence can be claimed between the proposed commericializable formulation and the current clinical formulation. Specifically, if the 90% confidence intervals of the ratio for Area under the curve (AUC) and maximum concentration (CMax) are within the 80%-125% guidance limits.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: Treatment A-B Drug: Treatment B-A Phase 1

Detailed Description:
A bioequivalence (BE) study between two formulations of PF-00299804.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: A Phase 1 Open-Label Study Of Pf-00299804 In Healthy Volunteers To Demonstrate The Bioequivalence Of The Proposed Commercializable Formulation Administered As One 45-Mg Tablet Relative To Three 15-Mg Clinical Formulation Tablets
Study Start Date : April 2011
Actual Primary Completion Date : May 2011
Actual Study Completion Date : May 2011

Arm Intervention/treatment
Experimental: Sequence 1
Subjects will receive clinical formulation (treatment A) followed by commercializable formulation (treatment B).
Drug: Treatment A-B
Subjects to receive 3 X 15 mg tablets of the clinical formulation in first period then 1 x 45 mg tablet of the commericializable formulation in 2nd period.
Experimental: Sequence 2
Subjects will receive commercializable formulation (treatment B) followed by clinical formulation (treatment A).
Drug: Treatment B-A
Subjects to receive 1 x 45 mg tablet of the commericializable formulation in first period then 3X 15 mg tablets of the clinical formulation in 2nd period.

Primary Outcome Measures :
  1. Plasma AUCinf of of PF 00299804 [ Time Frame: 6-8 weeks ]
  2. AUClast of PF 00299804 [ Time Frame: 6-8 weeks ]
  3. Cmax of PF 00299804 [ Time Frame: 6-8 weeks ]

Secondary Outcome Measures :
  1. Plasma AUCinf of PF 00299804. [ Time Frame: 6-8 weeks ]
  2. CL/F of PF 00299804. [ Time Frame: 6-8 weeks ]
  3. Tmax of PF 00299804. [ Time Frame: 6-8 weeks ]
  4. tlast of PF 00299804. [ Time Frame: 6-8 weeks ]
  5. t1/2 of PF 00299804. [ Time Frame: 6-8 weeks ]
  6. Plasma AUCinf of PF-05199265 [ Time Frame: 6-8 weeks ]
  7. AUClast of PF-05199265 [ Time Frame: 6-8 weeks ]
  8. Cmax of PF-05199265 [ Time Frame: 6-8 weeks ]
  9. Tmax of PF-05199265 [ Time Frame: 6-8 weeks ]
  10. tlast of PF-05199265 [ Time Frame: 6-8 weeks ]
  11. Safety laboratory tests, physical examination, concomitant medication and adverse event monitoring [ Time Frame: 6-8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy subjects including males between the ages of 18 and 55 years and/or females of non childbearing potential between the ages of 18 and 55 years. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG or clinical laboratory tests).
  • Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
  • An informed consent document signed and dated by the subject.
  • Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

  • Evidence or history of clinically significant dermatologic, hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Any condition possibly affecting drug absorption (eg, gastrectomy).
  • A positive urine drug screen.
  • Use of tobacco- or nicotine- containing products (or a positive urine drug cotinine test).
  • History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.
  • Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of study medication.
  • 12 lead ECG demonstrating QTc >450 msec or a QRS interval >120 msec at Screening. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTc or QRS values should be used to determine the subject's eligibility.
  • Pregnant or nursing females and females of childbearing potential including those with tubal ligation. To be considered for enrollment, women of 45 to 55 years of age who are postmenopausal (defined as being amenorrheic for at least 2 years) must have confirmatory FSH test results at Screening.
  • Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study medication. Herbal supplements and hormone replacement therapy must be discontinued at least 28 days prior to the first dose of study medication. Depo Provera must be discontinued at least 6 months prior to the first dose of study medication. As an exception, acetaminophen/paracetamol may be used at doses of less than 1 g/day. Limited use of non prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor.
  • Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to dosing.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • Unwilling or unable to comply with the Lifestyle Guidelines described in this protocol.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01313793

Pfizer Investigational Site
Bruxelles, Belgium, B-1070
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT01313793     History of Changes
Other Study ID Numbers: A7471022
First Posted: March 14, 2011    Key Record Dates
Last Update Posted: June 28, 2011
Last Verified: June 2011

Keywords provided by Pfizer:
Bioequivalence (BE) Study
Healthy Volunteers